Global Neuropathic Pain Market Outlook- Pipeline Review, H1 2016
©
Explanation
The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/145477
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
- The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuropathic Pain
Purchase a copy of Neuropathic Pain - Pipeline Review, H1 2016 Market visit @ http://www.orbisresearch.com/contact/purchase/145477
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned:
2-BBB Medicines BV
AbbVie Inc.
Achelios Therapeutics, Inc.
Adynxx, Inc.
Aestus Therapeutics, Inc.
Affectis Pharmaceuticals AG
Amura Holdings Limited
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
AstraZeneca Plc
BCI Pharma
BCN Peptides, S.A.
Benitec Biopharma Limited
BioDelivery Sciences International, Inc.
Biogen, Inc.
BioLineRx, Ltd.
Biomar Microbial Technologies
Bionomics Limited
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Cara Therapeutics, Inc.
Catalyst Biosciences, Inc.
Cavion LLC
Centrexion Corporation
Cerecor Inc.
Chromocell Corporation
Circuit Therapeutics, Inc.
CLL Pharma
Colby Pharmaceutical Company
ContraVir Pharmaceuticals, Inc.
Creabilis SA
Crinetics Pharmaceuticals, Inc.
Cytogel Pharma, LLC
Daewoong Pharmaceutical Co., Ltd.
Some Points From TOC:
Table of Contents
Table of Contents 2
Introduction 9
Neuropathic Pain Overview 10
Therapeutics Development 11
Neuropathic Pain - Therapeutics under Development by Companies 13
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 25
Neuropathic Pain - Pipeline Products Glance 27
Neuropathic Pain - Products under Development by Companies 31
Neuropathic Pain - Products under Investigation by Universities/Institutes 45
Neuropathic Pain - Companies Involved in Therapeutics Development 47
Neuropathic Pain - Therapeutics Assessment 168
Drug Profiles 204
Neuropathic Pain - Dormant Projects 506
Neuropathic Pain - Discontinued Products 529
Neuropathic Pain - Product Development Milestones 537
Appendix 546
The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/145477
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
- The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuropathic Pain
Purchase a copy of Neuropathic Pain - Pipeline Review, H1 2016 Market visit @ http://www.orbisresearch.com/contact/purchase/145477
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned:
2-BBB Medicines BV
AbbVie Inc.
Achelios Therapeutics, Inc.
Adynxx, Inc.
Aestus Therapeutics, Inc.
Affectis Pharmaceuticals AG
Amura Holdings Limited
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
AstraZeneca Plc
BCI Pharma
BCN Peptides, S.A.
Benitec Biopharma Limited
BioDelivery Sciences International, Inc.
Biogen, Inc.
BioLineRx, Ltd.
Biomar Microbial Technologies
Bionomics Limited
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Cara Therapeutics, Inc.
Catalyst Biosciences, Inc.
Cavion LLC
Centrexion Corporation
Cerecor Inc.
Chromocell Corporation
Circuit Therapeutics, Inc.
CLL Pharma
Colby Pharmaceutical Company
ContraVir Pharmaceuticals, Inc.
Creabilis SA
Crinetics Pharmaceuticals, Inc.
Cytogel Pharma, LLC
Daewoong Pharmaceutical Co., Ltd.
Some Points From TOC:
Table of Contents
Table of Contents 2
Introduction 9
Neuropathic Pain Overview 10
Therapeutics Development 11
Neuropathic Pain - Therapeutics under Development by Companies 13
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 25
Neuropathic Pain - Pipeline Products Glance 27
Neuropathic Pain - Products under Development by Companies 31
Neuropathic Pain - Products under Investigation by Universities/Institutes 45
Neuropathic Pain - Companies Involved in Therapeutics Development 47
Neuropathic Pain - Therapeutics Assessment 168
Drug Profiles 204
Neuropathic Pain - Dormant Projects 506
Neuropathic Pain - Discontinued Products 529
Neuropathic Pain - Product Development Milestones 537
Appendix 546